



Ophthotech Corp.
Investor Relations Department
Five Vaughn Drive
Suite 106
Princeton, NJ 08540
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: OPHT ¹

Last Trade:	2.63
Trade Time:	4:00 PM ET Jul 21, 2017
Change:	-0.06 (2.230%)
Day Range	2.62 - 2.71
52-Week Range	2.24 - 65.96
Volume	267,496
Market Cap. (\$M)	94.286
Shares Out (M)	35.850


¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.

... [\(more\)](#)

Stock Performance



Events [\[View all \]](#)

Jul 26, 2017 8:00 AM ET

[Ophthotech Corporation Second Quarter 2017 Results Conference Call](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Feb 28, 2017

[Annual Report \(10-K\)](#)

Apr 24, 2017

[Definitive Proxy Statement](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)

Nov 8, 2016

[Quarterly Report \(10-Q\)](#)

Aug 5, 2016

[Quarterly Report \(10-Q\)](#)